2025 United States Antibodies Contract Manufacturing Revenue Opportunities Report
Description
The 2025 United States Antibodies Contract Manufacturing Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in antibody contract manufacturing in the United States are Lonza, Thermo Fisher Scientific (including its Patheon division), Catalent, and AGC Biologics. Lonza is a major CDMO with extensive capabilities in biopharmaceuticals, supporting early development through commercial manufacturing. Thermo Fisher Scientific offers end-to-end pharmaceutical development and manufacturing solutions and acquired Patheon to enhance its capacity in drug substance and product services. Catalent is known for drug delivery technologies, biologics development, and clinical supply services. AGC Biologics specializes in biologics process development and manufacturing with expanded mammalian bioreactor capacities, supporting protein therapeutics and antibody drug development.
These companies leverage advanced technologies such as single-use bioreactors and digital platforms to meet growing demand driven by increasing R&D investments in biologics, personalized medicine, and antibody-drug conjugates (ADCs). The U.S. market is the largest globally, supported by a robust pipeline of FDA-approved biologics and frequent clinical trials involving antibody-based therapies. Their broad service offerings cover cell line development, protein expression, process scale-up, and commercial manufacturing. Continuous expansion, like AGC Biologics’ new facilities and Thermo Fisher’s acquisition strategies, confirm their leadership in supporting biopharmaceutical innovation and production.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in antibody contract manufacturing in the United States are Lonza, Thermo Fisher Scientific (including its Patheon division), Catalent, and AGC Biologics. Lonza is a major CDMO with extensive capabilities in biopharmaceuticals, supporting early development through commercial manufacturing. Thermo Fisher Scientific offers end-to-end pharmaceutical development and manufacturing solutions and acquired Patheon to enhance its capacity in drug substance and product services. Catalent is known for drug delivery technologies, biologics development, and clinical supply services. AGC Biologics specializes in biologics process development and manufacturing with expanded mammalian bioreactor capacities, supporting protein therapeutics and antibody drug development.
These companies leverage advanced technologies such as single-use bioreactors and digital platforms to meet growing demand driven by increasing R&D investments in biologics, personalized medicine, and antibody-drug conjugates (ADCs). The U.S. market is the largest globally, supported by a robust pipeline of FDA-approved biologics and frequent clinical trials involving antibody-based therapies. Their broad service offerings cover cell line development, protein expression, process scale-up, and commercial manufacturing. Continuous expansion, like AGC Biologics’ new facilities and Thermo Fisher’s acquisition strategies, confirm their leadership in supporting biopharmaceutical innovation and production.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
